SMHGF (SMHGF PINK) stock market data APIs
$0.6978
0(0%)
as of October 20, 2025
Try our APIs with
free plan!
SMHGF Financial Data Overview
Price chart is built with
Anychart
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN simnotrelvir tablets and ritonavir tablets. The company also offers promotional services for pharmaceutical products. In addition, it engages in the manufacture of pharmaceutical ingredients and its property management business. The company was founded in 1995 and is headquartered in Nanjing, China.
Prev. Close
0.6978
Open
0.6978
High
0.6978
Low
0.6978
52 wk Range
0.6699-0.7585
Market Cap
4 397 M
P/E Ratio
17.305
Shares Outstanding
2 596 M
Revenue
7 107 M
Dividends (Yield)
0.2311
Beta
0.517
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SMHGF data using free add-ons & libraries
Get SMHGF Fundamental Data
SMHGF Fundamental data includes:
- Net Revenue: 7 107 M
- EBITDA: 1 485 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SMHGF News
New
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
NextCure First U.S. patient dosed at a mid-tier dose level where multiple responses have been observed Multi-regional trial to accelerate time to proof-of-concept data in 1H 2026 BELTSVILLE, Md. and...
Asian Stocks Estimated Below Intrinsic Value In October 2025
As global markets navigate a landscape marked by cautious monetary policies and economic uncertainties, Asian stock markets have shown resilience with notable gains in regions like Japan and mainland ...
Idorsia: Simcere To Introduce QUVIVIQ To Patients In China
(RTTNews) - Idorsia announced that Simcere Pharmaceuticals has launched QUVIVIQ or daridorexant in China. QUVIVIQ, Idorsia's dual orexin receptor antagonist, is indicated for the treatment of adult pa...
Simcere Pharmaceutical Group (SEHK:2096) Completes HK$2 Billion Follow-On Equity Offering
Simcere Pharmaceutical Group recently completed a follow-on equity offering, raising HKD 1.57 billion, which coincided with a 10.69% increase in the company's share price over the past month. The acce...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
